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Abstract
Mitral stenosis (MS) is the most important long-term sequel of rheumatic fever (RF). MS 
is associated with deterioration of the functional status of the patients and worsens their 
long-term prognosis. Percutaneous balloon mitral valvuloplasty (BMV) is an effective 
and safe method in treating rheumatic MS when performed by an experienced operator 
in a carefully selected patient. A successful BMV procedure results in reducing the symp-
toms and improving the long-term outcome of the patients. Of the different proposed 
techniques, the Inoue balloon technique is the most frequently used. Appropriate patient 
selection using clinical and echocardiographic characteristics is of paramount impor-
tance for achieving acceptable final results. Complications are infrequent but can cause 
significant morbidity and even mortality. Special subgroups of patients might also ben-
efit from BMV, including pregnant women, older patients with rigid valves, and those 
with mitral valve restenosis.
Keywords: balloon valvuloplasty, Inoue technique, mitral stenosis, rheumatic heart 
disease, transseptal catheterization
1. Introduction
Rheumatic fever (RF) develops as the consequence of autoimmune reaction to group A beta-
hemolytic streptococcal pharyngeal infection [1]. Cardiac involvement is the most important 
manifestation of RF and mainly presents an acute endocarditis and valvulitis. The following 
inflammatory and hemodynamic changes involving the cardiac valves insulted by the acute 
RF could result in long-standing rheumatic heart disease (RHD). The natural course of RHD 
depends on the severity of the initial attack and the frequency of recurrences. Unlike in devel-
oped countries, RHD is not infrequently seen in many areas of the world. Indeed, some coun-
tries have reported persistently high or even increasing incidence of RF and subsequent RHD 
during the recent decades [2]. All cardiac valves could be involved in patients with RHD. 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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The mitral valve is almost always affected in clinically manifested patients, followed by the 
aortic and tricuspid valves. Mitral stenosis (MS) is the cardinal valvular lesion in RHD and 
is particularly amenable to transcatheter therapy when it is isolated or dominant and the 
anatomy is favorable. When left untreated, severe MS deteriorates the functional status of the 
patients and worsens their long-term outcomes [3]. Rarely, other etiologies might cause MS 
(i.e., connective tissue disorders, drugs, and congenital abnormalities). Today, degenerative 
calcified MS, failure of the bioprosthetic mitral valve, and overcorrection of mitral regurgi-
tation (MR) are increasingly seen. Unlike rheumatic MS, these non-rheumatic mitral valve 
obstructions are not associated with commissural fusion and are not generally relieved by 
percutaneous balloon mitral valvuloplasty (BMV). When applied in correctly selected sub-
jects and performed by experienced operators, a successful BMV procedure can improve 
symptoms and long-term survival of the patients and is, therefore, the method of choice in 
the treatment of patients with severe rheumatic MS [4, 5].
2. Evaluation of severity
2.1. Echocardiography
Echocardiography is essential in the diagnosis and quantification of the severity of MS. 
Transthoracic echocardiography (TTE) provides sufficient data in most patients and should be 
performed in patients at initial presentation, in those with changing symptoms, and in asymp-
tomatic patients periodically (Figure 1). It shows the restriction of the mitral valve opening 
caused by commissural fusion and the so-called doming of the mitral valve, thickness and calcifi-
cation of the leaflets, and chordal thickening. A mitral valve area (MVA) ≤ 1.5 cm2 and a pressure 
half-time (PHT) ≥ 150 ms correspond to severe MS. PHT is affected by left ventricular (LV) dia-
stolic dysfunction and the severity of mitral and aortic regurgitation, while planimetry-derived 
MVA is more accurate and should be used for decision-making in most patients [6]. Mitral valve 
resistance might be a better predictor of hemodynamic burden of MS and can be used to deter-
mine the need for BMV in borderline cases [7]. The other parameters that are evaluated include 
transmitral valve gradient, MR severity, concomitant valvular involvement, atrial size, left and 
right ventricular functions, and pulmonary arterial pressure. Transesophageal echocardiography 
(TEE) is valuable when the images derived from TTE are not satisfactory or when the patient is 
candidate for BMV to rule out clots in the left atrium (LA) and the left atrial appendage (LAA) as 
well as for a detailed evaluation of MR severity.
2.2. Hemodynamic study
Cardiac catheterization, aside from guiding the procedure, is indicated when  echocardiography 
is nondiagnostic. It is not routinely indicated; however, it is necessary when the results from 
echocardiography are ambiguous, when the severity of other valvular lesions is evaluated, 
and when there is a suspicion of coronary artery disease. Before BMV, measurement of the 
mitral valve gradient, pulmonary arterial pressure, and MVA using the Gorlin equation can 
be helpful in borderline cases and for confirming the severity of MS.
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3. Patient selection
3.1. Indications
BMV causes the splitting of the fused commissures and increases the MVA. Patients with 
symptomatic severe rheumatic MS with an MVA ≤ 1.5 cm2 should be thoroughly evaluated 
and subjected to BMV if the valvular morphology is suitable [8] (Figure 2). Dyspnea is the 
most common symptom but it is not prominent in some patients. Additional attributable 
symptoms are exercise intolerance, fatigue, and chest pain. Given the proved long-term effi-
cacy of BMV, even minimal symptoms should be regarded as the indication for intervention 
considering that this procedure is relatively safe in experienced hands. Patients with less 
severe obstruction (MVA > 1.5 cm2) remain asymptomatic for many years and do not need 
non-pharmacologic intervention [9]. In addition, asymptomatic patients with very severe 
MS (MVA ≤ 1 cm2) are reasonable candidates for BMV. In patients with asymptomatic severe 
MS (MVA ≤ 1.5 cm2), BMV can be performed if pulmonary hypertension is present (pul-
monary artery systolic pressure ≥ 50 mm Hg at rest and ≥ 60 mm Hg with exercise). Atrial 
fibrillation (AF) worsens the prognosis in patients with severe MS through deteriorating 
functional status, progressing structural damage, and increasing thromboembolic risk [10, 
11]. Meanwhile, AF can be an indicator of progressive MS [12]. As a result, new AF in a 
Figure 1. 3D echocardiography revealing bicommissural fusion, fish-mouth appearance of the mitral valve, and planimetry-
derived mitral valve area of 0.89 cm2.
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patient with severe MS mandates special consideration and might be an indication for BMV 
[8, 13]. The other potential indication for BMV is the presence of symptoms in a patient with 
mild MS (MVA > 1.5 cm2) with the evidence of significant obstruction (pulmonary capillary 
wedge pressure >25 mm Hg) during exercise. BMV as a therapeutic option in a patient with 
the latter scenario should be only considered after a comprehensive hemodynamic study 
and the exclusion of other potential causes. In recent practice, we encounter a subset of very 
symptomatic old patients with severe MS and unfavorable valve anatomy who were not 
candidated for mitral valve replacement (MVR) because of their comorbidities. BMV might 
be considered in these patients, although the immediate result is suboptimal, complications 
are more frequent, and long-term efficacy is limited [8, 14].
3.1.1. Anatomic eligibility
When the patient is considered a likely candidate for BMV, morphologic characteristics should 
be evaluated using echocardiography. The Wilkins score comprises four echocardiographic 
characteristics of the mitral valve, including leaflet mobility, leaflet thickness, leaflet calcifica-
Figure 2. Management of patients with severe mitral stenosis.
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tion, and subvalvular apparatus, each given a 1- to 4-point value according to the predefined 
definitions [15]. Patients with Wilkins scores ≤ 8 are particularly suitable for BMV. This means 
that the mitral valve is sufficiently pliable and most often does well in response to balloon dila-
tation. In our practice, most patients have Wilkins scores between 8 and 10. BMV in these rela-
tively fibrotic, rigid, and calcified valves often results in unpredictable and somehow suboptimal 
acute and late final MVAs, but many patients still experience acceptable and durable functional 
recovery, deferring eventual surgery. The ideal patients do not have MR more than moderate in 
severity, and the LA and LAA are free from thrombi. Significant concomitant valvular involve-
ment including more-than-moderate aortic stenosis and regurgitation and tricuspid stenosis 
should not be presented. Secondary tricuspid regurgitation, even if it is significant, is not a limit-
ing factor and most patients experience reduction in its severity after successful BMV.
3.2. Contraindications
When the Wilkins score is >10, BMV is generally ineffective and is, instead, associated with a 
higher incidence of severe MR and should, therefore, be avoided. The severity of preprocedural 
MR predicts the possibility of severe MR after the procedure that is associated with a poor long-
term outcome of BMV. Moderate-to-severe MR (≥3+) is regarded a contraindication for BMV 
considering that the procedure itself aggravates MR in many cases. LA thrombi or thrombi 
on the interatrial septum are the absolute contraindications of transseptal puncture and BMV, 
whereas LAA thrombi are considered a relative contraindication. Bicommissural and fluoro-
scopic valve calcification are associated with a poor outcome following BMV [16]. When the 
commissural fusion is absent, BMV is ineffective and should not be used. Many patients with 
MS receive oral anticoagulation because of AF. Transseptal puncture should be avoided in the 
presence of an International Normalized Ratio (INR) >1.5 or within 4 hours after the adminis-
tration of intravenous heparin. The contraindications for BMV are outlined in Table 1.
Wilkins score > 10
Concomitant mitral regurgitation ≥ 3+
Concomitant aortic regurgitation ≥ 3+
Left atrial thrombus
Left atrial appendage thrombus (relative)
Severe or bicommissural calcification
Fluroscopic valve calcification
Absence of commissural fusion
Bleeding diastasis, INR > 1.5
Other cardiac disease (coronary, valvular, congenital) necessitating cardiac surgery
BMV, balloon mitral valvuloplasty; INR, International Normalized Ratio.
Table 1. Contraindications to BMV.
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4. Procedure
4.1. Patient preparation
General considerations resemble those of the other interventional procedures. Fasting is needed 
for at least 8 hours for solid foods and 3 hours for liquids. The patient should be hydrated 
according to the standard protocols for the prevention of contrast-induced acute kidney 
injury. BMV and even transseptal catheterization can be performed with no or minimal con-
trast media; accordingly, contrast-induced nephropathy is not a major issue. Rapid heart 
rate in patients with AF might interfere in stable balloon dilatation and should be controlled. 
No specific pharmacologic pretreatment is needed before BMV, but most medications (beta-
blockers, calcium channel blockers, digoxin, etc.) are routinely continued. Warfarin should be 
withheld for 3 days before the procedure. Instead, heparin is needed to be infused while the 
patient is under therapeutic INR levels (INR < 2). Heparin infusion is stopped 4 hours before 
the patient arrives at the catheterization laboratory. Preprocedural TEE is of paramount 
importance to exclude LA/LAA thrombi in all patients and should be performed preferably 
just before but not more than 2 weeks before BMV because the possibility of LA/LAA clot can-
not be completely ruled out even with sinus rhythm. Antibiotic prophylaxis is not routinely 
prescribed before or during the procedure, but it might be needed if the aseptic barrier has 
been disrupted.
4.2. Anesthesia
Most BMV procedures can be performed under mild conscious sedation. Rarely, the patient 
has a tender septum and experiences discomfort during the transseptal puncture and might 
need analgesia and more sedation and exceptionally, general anesthesia. General anesthesia 
is also needed in uncooperative or unstable patients or when TEE is used to guide transseptal 
catheterization and BMV in difficult cases.
4.3. Approaches
The antegrade transvenous transseptal approach is most commonly used. The right femo-
ral vein is preferred because appropriate alignment of the transseptal needle with the inter-
atrial septum facilitates septostomy. The left femoral and rarely jugular veins also can be 
used [17, 18]. The femoral or radial arteries are used for hemodynamic monitoring, perform-
ing catheterization, and guiding the transseptal puncture. The retrograde non-transseptal 
approach from the femoral artery has been utilized with acceptable results; nonetheless, 
higher risks of arterial damage and more hemodynamic burden arising from the trans-aortic 
passage of the balloon catheter have limited its use [19].
4.4. Transseptal puncture
It is the first and very important step in performing a successful BMV. The transseptal puncture 
is the source of complexity and complications in many patients undergoing BMV. Although 
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the puncture site is less important than that in the MitraClip and LAA occlusion, a central or 
slightly low puncture is recommended. An appropriate puncture site facilitates the crossing 
of the mitral valve by the balloon catheter. A low puncture is especially important when the 
double balloon or metallic commissurotome is used. Fluoroscopy is the fundamental imaging 
tool used to guide the transseptal puncture but TEE and intracardiac echocardiography (ICE) 
can help in difficult cases or for performing a site-specific puncture.
4.5. Techniques
Thus far, several techniques have been introduced. Of those, the Inoue balloon technique has 
gained the most popularity because of its safety and effectiveness.
4.5.1. Metallic commissurotome
A reusable metallic dilator has been developed to decrease the cost of the procedure. It has 
been reported that the procedure is safe, with good acute and long-term results comparable 
to the Inoue technique [20]. The risk of LV perforation and subsequent tamponade with the 
metallic device should be considered. The more demanding nature of the procedure and con-
cerns about the reused devices have limited this technique in many countries.
4.5.2. Double balloon technique
In this antegrade transseptal technique, a balloon-tipped catheter is used to cross the mitral 
valve followed by introducing an exchange-length (260 cm) wire through the catheter lumen 
securing its end in the LV or the descending aorta. A second wire should be introduced by 
the same way or using a dual-lumen catheter. Two balloons (15–20 mm in diameter) are 
introduced over the wires and positioned across the mitral valve and inflated simultaneously 
[21]. In theory, two balloons side-by-side can exert a more focused pressure on the commis-
sures than a single balloon. This technique is relatively safe and effective but is not widely 
used because of being more time-consuming than the Inoue technique and more hazardous 
because of the risk of wire-induced LV perforation. The multi-track system is a newer variant 
of double-balloon valvuloplasty that provides effectiveness of double-balloon inflation using 
a single wire.
4.5.3. Inoue balloon technique
The Inoue balloon catheter is a dumbbell-shaped balloon that self-positions in the mitral valve 
because of its unique physical properties and mode of inflation. It has been made from two 
latex layers and a middle nylon layer, giving the balloon its specialized shape and inflation 
characteristics. The balloon inflates in three sequential stages. The distal end of the balloon 
inflates at the first stage, followed by the proximal half, to facilitate positioning across the 
mitral valve. Finally, inflation of the waist portion of the balloon separates commissures [22]. 
Several balloon sizes are available (24, 26, 28, and 30 mm in diameter), and each can be inflated 
in a 4-mm diameter zone. The reference balloon size (RS) is calculated based on the height of 
the patient (patient’s height in cm rounded to the nearest 0, divided by 10, and 10 added to 
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the ratio) or the newly introduced method of inter-commissural diameter [23–25]. In patients 
with pliable valves, an RS-matched balloon is selected but in patients with pre-existing MR, 
severe commissural calcification, significant subvalvular involvement, or very severe MS 
(MVA ≤ 0.5 cm2), as well as in patients with special situations where they do not need very 
large valve areas or in patients whose complications are more common and difficult to man-
age (i.e., old patients, pregnancy, etc.), a balloon 1 size smaller than the RS is chosen [23].
Immediately after the transseptal puncture, confirming the position of the needle tip in the 
LA and septal dilation, 70–100 IU/kg of heparin is administered intravenously to achieve 
an activated clotting time (ACT) of 250–300 s. A spring pigtail-like stiff wire is placed in the 
LA and a 14-French dilator is used to dilate both the femoral subcutaneous track and the 
atrial septum. A previously vented, de-aired, and calibrated slenderized balloon is sent to 
the LA over the wire and then reshaped to its original deflated configuration by removing 
the stretching tube and the wire and pulling back the gold tube. If there is any resistance 
when crossing the inguinal area, redilating the area using a larger dilator definitely helps. 
To overcome the resistance across the septum, the operator turns the balloon catheter in one 
or other directions or dilates the septum with a peripheral balloon (6–8 mm in diameter). By 
changing the projection from the anteroposterior (AP) to the right-anterior oblique (RAO), 
the operator introduces the stylet and while the balloon is partially inflated at its distal end 
acting as a floating balloon, the operator directs the balloon catheter toward and across the 
mitral valve with a combination of rotating anticlockwise and pulling the stylet and pushing 
the balloon. Free movement of the balloon in the LV toward the apex shows that the balloon 
has not been entrapped in the subvalvular apparatus and papillary muscles. In the final step, 
the distal half is fully inflated and the balloon is retracted to catch the mitral valve, followed 
by the inflation of the proximal and central part of the balloon until the disappearance of the 
waist (Figure 3). If any kind of distortion in the contour of the balloon is seen, the inflation 
should not be continued because of the possibility of balloon entrapment and subsequent 
severe MR. The balloon should be inflated with a diluted contrast medium (contrast-saline 
ratio of 1:5) to minimize the inflation-deflation period (2–4 s). It is recommended that the 
balloon be inflated in a stepwise fashion started 2–4 mm below the calculated RS. The bal-
loon size is then increased 1 mm in each step, and the procedure should be stopped if any of 
the following criteria is met: (1) final MVA >1.5 cm2 or an increase in the valve area of 50%, 
(2) a fall in the mean gradient by 50% or from >10 to <5 mm Hg, (3) complete opening of at 
least one commissure, and (4) appearance or aggravation of MR >1+ (Table 2).
4.6. Surveillance of the procedure
Imaging modalities combined with fluoroscopy can help to guide the procedure, assess 
the results, and diagnose complications. Evaluation of the mean LA pressure, transmitral 
valve gradient, and the contours of LA pressure between the inflations might help but they 
are subjected to variations and are not reliable markers of the success or occurrence of the 
complications. In addition, the MVA, estimated by the Gorlin formula, is affected by atrial 
shunt and MR. TTE is integral to guiding the procedure and should be performed between 
the inflations and at the end of BMV. The planimetry-derived MVA, splitting of the com-
missures, and the severity of MR can be readily and reliably assessed in many patients 
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using TTE. TEE needs general anesthesia and is difficult to perform in the catheterization 
laboratory but is helpful in patients with poor echo window and in pregnant women in 
whom fluoroscopy is of concern. The TEE also provides superior views to verify the posi-
tioning of the balloon in the mitral valve in difficult cases (Figure 4).
4.7. Postprocedural considerations
After the removal of the balloon catheter, the venous access site should be compressed to 
achieve hemostasis. The arterial access is managed depending on the site (femoral or radial). 
The patient should be monitored overnight in a step-down unit to detect complications. Most 
patients can be discharged within 1–2 days. In patients with AF, heparin can be restarted 
3–4 hours after sheath removal, followed by warfarin. Bedside TTE can detect late accumu-
lation of pericardial effusion. The patients who have developed complications need to be 
closely monitored in the intensive care unit. The PHT is affected by the change in compliance 
immediately after BMV; therefore, it is recommended to calculate the MVA by the PHT 2–3 
Figure 3. Inoue technique. Inflation of distal end of the balloon, retracted toward mitral valve (A–B). Inflation of proximal 
half catching the commissures in between (C). Full inflation of the balloon disappearing the waist (D).
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Figure 4. Postprocedural 3D imaging of the mitral valve revealing final mitral valve area of 1.45 cm2.
Balloon reference size (RS)
 – 0.1 × height (cm) + 10 (after rounding the patient’s height to the nearest zero) or
 – 30 for height >180 cm, 28 for 160–180 cm, 26 for <160 cm or
 – Inter-commissural diameter measured on parasternal short-axis echocardiogram view
Balloon size selection
 – RS-matched if the patient is young, valve is pliable, and MR is absent or less than 1+
 – 1 size smaller than the RS if the valve is rigid, MR is >1+ and in high risk subjects (i.e., pregnancy, old age)
Inflation mode
 – Start 2 mm below the RS in low risk patients, 4 mm in high risk patients
 – Inflate in 1 mm increments under echocardiographic guidance
Closing criteria
 – MVA > 1.5 cm2
 – 50% increase in the MVA
 – 50% fall in mean gradient
 – Fall in mean gradient from >10 mm Hg to <5 mm Hg
 – Appearance or aggravation of MR > 1+
 – Complete opening of at least one commissure
MR, mitral regurgitation; MVA, mitral valve area; RS, reference size.
Table 2. Inoue balloon selection and inflation protocol.
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days later. Direct planimetry yields the most accurate estimate of postprocedural MVA, but it 
might overestimate the MVA in the first day after the procedure and should be performed 1–2 
days later allowing for the early loss [26]. TEE is not routinely recommended after successful 
BMV. If there is severe MR, TEE is essential for detecting its exact mechanism, which is impor-
tant for further decision regarding conservative or invasive intervention.
5. Complications
General complications (i.e., vascular injury, arrhythmias, and contrast allergy) might occur 
and should be managed accordingly. Mortality has been reported in 1–2% and is mainly due 
to cardiac tamponade or the poor underlying condition of the patients [27].
5.1. Cardiac perforation and tamponade
Hemopericardium is the main complication of BMV and is seen in 1% of patients. The trans-
septal puncture is the source of most cardiac perforations during BMV. The anatomic factors 
of patients such as atrial enlargement and chest deformities increase the risk. TEE and ICE 
can guide the transseptal puncture, especially when the operator is inexperienced or in diffi-
cult cases, and reduce the risk of hemopericardium. Double-balloon mitral valvuloplasty and 
metallic commissurotome are associated with the risk of LV perforation because the wires are 
handled in the LV cavity. The management depends on the severity of pericardial effusion 
and the mechanism and consists of closed observation, reversal of heparin, pericardiocente-
sis, and emergent surgery. When the hemopericardium happens after septal dilation or LV 
perforation, especially if it is retractable despite prompt drainage, surgery is necessary to be 
proceeded.
5.2. Systemic embolism and stroke
While BMV might decrease the long-term risk of systemic embolism in patients with MS, 
the procedure itself can be associated with embolic stroke in about 1–1.5% of patients [28]. 
Meticulous anticoagulation and de-airing of the equipment and preprocedural TEE to rule 
out LA thrombi will reduce the chance of systemic embolism. An undiagnosed pre-existing 
LA/LAA clot and thrombus formation during the procedure are the main mechanisms, but 
calcium or air embolism also has a role.
5.3. Severe MR
Commissural opening, which is the main mechanism of increasing the MVA, is associated 
with aggravating MR after BMV in many patients but most are not significant and usually 
do not worsen functional status and long-term prognosis of the affected patients. Severe MR 
occurs in 2–15% of patients mainly because of non-commissural valve tearing and chordal 
rupture but exaggerated commissural splitting and rarely papillary muscle rupture are 
responsible [27, 29–31]. The incidence of severe MR does not change with different techniques 
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(Inoue vs. double balloon and metallic commissurotomy) [20, 32]. Unfavorable valve anat-
omy and inappropriate balloon sizing and inflation protocol predict the occurrence of severe 
MR after BMV, but their predictive value is not high and it can occur unpredictably in some 
patients with good morphologic features. Most patients need subsequent mitral valve surgery 
(mostly MVR) because severe MR is associated with the deterioration of functional status and 
poor outcomes. The timing of the surgery is determined by clinical tolerance, hemodynamic 
stability, mechanism of MR, and surgical risk. Most patients with severe MR can be man-
aged conservatively and are subjected to mitral valve surgery on a scheduled basis. In a small 
number of patients who remain severely symptomatic despite initial medical therapy or who 
experience hemodynamic instability, or when the mechanical background of MR is severe 
and irreversible, urgent MVR should be planned. Patients with moderate MR can be often 
followed-up for a long period of time and some even experience a reduction in the severity of 
MR over time [33, 34].
5.4. Atrial septal defect
A wide range of frequency has been reported (10–90%) depending on modality that has been 
used for detection [35, 36]. Most defects decrease in size or disappear over time and have no 
adverse effects [37]. Infrequently, the defect is large enough to cause significant left-to-right 
shunting, especially when there is a significant residual mitral valve gradient and, therefore, 
surgical repair should be performed along with mitral valve surgery. Percutaneous closure 
of post-BMV residual atrial septal defects has not been reported and seems to be unsuccess-
ful. In rare circumstances, right-to-left shunting and subsequent paradoxical embolism might 
happen in patients with significant pulmonary hypertension.
5.5. Emergent surgery
Rarely, patients need emergent surgery because of the complications. The most frequent 
cause is hemopericardium unresponsive to pericardiocentesis, especially when it happens 
after septal dilation and LV perforation. In most patients, the surgery includes repair of the 
tearing and MVR. Severe MR can also necessitate urgent surgery in some patients.
6. Special considerations
6.1. LAA/LAA thrombus
If the patient is clinically stable, BMV can be postponed for 3–6 months, while the patient receives 
intensive anticoagulation with an INR of 3–3.5. If repeated TEE shows that the clot has been 
completely resolved, BMV can be safely performed. If the thrombus persists, the patient should 
be referred for open mitral valvulotomy or MVR. If surgery is not a feasible option, BMV is not 
possible to be deferred, and the thrombus is small, fixed, and confined to the LAA, experienced 
operators might do BMV ensuing that the wire and balloon catheter are kept away from the LAA.
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6.2. Previous valvulotomy
Restenosis is not infrequent after percutaneous or surgical commissurotomy. As a grow-
ing population, these patients account for one-third of all MS patients in developed coun-
tries. Depending on the mechanism, commissural fusion is not predominant in some cases, 
which limits the role of BMV as an effective intervention. BMV is a feasible option in 
patients with significant restenosis after percutaneous, closed, or open valvulotomy as 
long as the commissural fusion is present and valve anatomy is favorable [38]. Immediate 
and mid-term results are encouraging but might be slightly less satisfactory than with de 
novo MS.
6.3. Pregnancy
Significant hemodynamic burden caused by pregnancy, labor, and delivery might be not 
well-tolerated by patients with severe MS. Patients with severe MS often experience wors-
ening of the symptoms or become symptomatic for the first time during pregnancy. Not 
surprisingly, MS is detected for the first time in many patients during pregnancy. If left 
untreated, severe MS is associated with a high maternal and perinatal mortality, not least 
in those who are highly symptomatic or have AF. The intrapartum and postpartum period 
carries the highest risk in these patients [39]. In patients who remain symptomatic, despite 
medical therapy, BMV should be performed because the surgery is associated with very high 
risk of fetal death [40]. BMV is an effective and safe method for relieving MS in pregnant 
women when performed by highly experienced operators. It has been reported that BMV 
during pregnancy has a high success rate and excellent short-term results and provides 
normal eventless deliveries in the majority of patients. In addition, stillbirth is infrequent 
and most babies have normal growth and developmental patterns [41, 42]. From a practical 
point of view, to avoid radiation during organogenesis, the procedure should be performed 
after the 12th week or ideally after the 20th week. The lead shields should cover the abdo-
men and pelvis and behind the patient. Fluoroscopy time should be minimized as much as 
possible. The Inoue balloon technique seems to be the preferred method considering shorter 
fluoroscopy time and inflation-deflation cycle of the balloon. Special care should be taken 
about the gravid uterus, possible difficulties in the passage of the equipment through the 
compressed inferior vena cava, and the chance of hypotension and subsequent fetal distress 
when the mother lies for a long period of time. The balloon size should be selected with 
great caution. A balloon 1 size smaller than the RS-matched is preferable in borderline cases. 
The more conservative method of measuring the inter-commissural diameter can be used for 
balloon sizing in these patients. The stepwise balloon dilatation of 0.5 mm is advisable, and 
aggressive balloon dilatation is necessarily avoided because it might result in severe MR and 
subsequently needs urgent surgery, which is unacceptably hazardous to mother and child. 
TEE can assist in the transseptal puncture, balloon positioning, and stepwise inflations and 
can limit fluoroscopy time. However, it needs general anesthesia in many cases, requiring 
that the position of the patient be changed to lateral decubitus to prevent hypotension in 
prolonged procedures.
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6.4. Inoperable patients
BMV might be an option in patients who are old and have significant comorbidities. Given 
the suboptimal results and the higher incidence of complications arising from unfavorable 
morphologic characteristics of the mitral valve and poor condition of patients, BMV should 
be only used in highly symptomatic patients. In these patients, a more conservative BMV 
strategy is suggested. The Inoue technique is more appropriate because it is less demanding 
and provides a faster and smoother procedure. A balloon 1 size smaller than the RS is chosen, 
followed by a further stepwise dilatation of 0.5 mm. The final result should be judged on an 
individualized basis. Definitely, a smaller MVA is sufficient in most patients in exchange for 
severe MR and the difficulty in its management.
7. Results
7.1. Immediate results
A good immediate result is defined as an MVA > 1.5 cm2 without MR more than moderate 
and is most probably achieved in patients with favorable morphologic features; nonetheless, 
other factors including age, history of previous commissurotomy, smaller baseline MVA, pre-
existing MR, pulmonary artery pressure, sinus rhythm, functional status, and technical issues 
are also determining [43, 44].
7.2. Long-term results
When BMV has a good acute result, the long-term survival rate is high and the need for reinter-
vention is infrequent. Anatomical characteristics and age are important predictors of long-term 
outcomes. Midterm outcomes (3–7 y) are favorable and comparable with open mitral valvu-
lotomy and better than closed mitral valvulotomy [5].
Restenosis can occur after successful BMV, but its incidence is difficult to determine due to 
the absence of a uniform definition and different follow-up periods in the studies. An MVA 
< 1.5 cm2 or a 50% loss in the initial MVA is generally defined as restenosis. The possible mech-
anisms include suboptimal initial results, recurrent rheumatic attacks, and a hemodynamic-
related degenerative process. In patients with symptomatic severe restenosis, repeat BMV or 
mitral valve surgery should be selected according to the guidelines.
8. Conclusions
MS as the long-standing sequel of RHD is rare in developed countries, whereas it is still seen 
frequently in many areas of the world. BMV as a minimally invasive transcatheter technique 
is the method of choice in the treatment of these patients. In successful cases, BMV results in 
a very high survival rate and freedom from symptoms. Appropriate patient selection and a 
competent technique are the key factors for achieving an excellent result.
Interventional Cardiology112
Acknowledgements
The authors like to thank Farshad Amouzadeh for his great assistance in the linguistic editing 
of this chapter.
Author details
Hamidreza Sanati* and Ata Firoozi
*Address all correspondence to: sanati56@yahoo.com
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research 
Center, Tehran, Iran
References
[1] Carapetis, J.R., M. McDonald, and N.J. Wilson, Acute rheumatic fever. The Lancet, 2005. 
366(9480): pp. 155-168.
[2] Iung, B. and A. Vahanian, Epidemiology of valvular heart disease in the adult. Nature Reviews 
Cardiology, 2011. 8(3): pp. 162-172.
[3] Rahimtoola, S.H., et al., Current evaluation and management of patients with mitral stenosis. 
Circulation, 2002. 106(10): pp. 1183-1188.
[4] Iung, B., et al., Late results of percutaneous mitral commissurotomy in a series of 1024 patients 
analysis of late clinical deterioration: frequency, anatomic findings, and predictive factors. 
Circulation, 1999. 99(25): pp. 3272-3278.
[5] Cruz-Gonzalez, I., et al., Predicting success and long-term outcomes of percutaneous mitral 
valvuloplasty: a multifactorial score. The American Journal of Medicine, 2009. 122(6): pp. 
581. e11-581. e19.
[6] Mohan, J.C., et al., Does chronic mitral regurgitation influence Doppler pressure half-time–
derived calculation of the mitral valve area in patients with mitral stenosis? American Heart 
Journal, 2004. 148(4): pp. 703-709.
[7] Sanati, H., et al., Mitral valve resistance determines hemodynamic consequences of severe 
rheumatic mitral stenosis and immediate outcomes of percutaneous valvuloplasty. Echocardiog-
raphy. 2017;34:162-168.
[8] Nishimura, R.A., et al., 2014 AHA/ACC guideline for the management of patients with val-
vular heart disease: a report of the American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines. Journal of the American College of Cardiology, 2014. 
63(22): pp. e57-e185.
Percutaneous Balloon Mitral Valvuloplasty
http://dx.doi.org/10.5772/67757
113
[9] Horstkotte, D., R. Niehues, and B. Strauer, Pathomorphological aspects, aetiology and natu-
ral history of acquired mitral valve stenosis. European Heart Journal, 1991. 12(suppl B): pp. 
55-60.
[10] Moretti, M., et al., Prognostic significance of atrial fibrillation and severity of symptoms of heart 
failure in patients with low gradient aortic stenosis and preserved left ventricular ejection frac-
tion. The American Journal of Cardiology, 2014. 114(11): pp. 1722-1728.
[11] Halperin, J.L. and R.G. Hart, Atrial fibrillation and stroke: new ideas, persisting dilemmas. 
Stroke, 1988. 19(8): pp. 937-941.
[12] Vahanian, A., et al., Guidelines on the management of valvular heart disease (version 2012). 
The Joint Task Force on the Management of Valvular Heart Disease of the European Society 
of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). 
Giornale Italiano di Cardiologia, 2013. 14(3): pp. 167-214.
[13] Kirchhof, P., et al., 2016 ESC Guidelines for the management of atrial fibrillation developed 
in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the 
European Society of Cardiology (ESC). Developed with the special contribution of the European 
Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation 
(ESO). European Journal of Cardio-Thoracic Surgery, 2016. p. ezw313.
[14] Ramondo, A., et al., Relation of patient age to outcome of percutaneous mitral valvuloplasty. 
The American Journal of Cardiology, 2006. 98(11): pp. 1493-1500.
[15] Wilkins, G., et al., Percutaneous balloon dilatation of the mitral valve: an analysis of echocar-
diographic variables related to outcome and the mechanism of dilatation. British Heart Journal, 
1988. 60(4): pp. 299-308.
[16] Ribeiro, P.A., et al., Mechanism of mitral valve area increase by in vitro single and double bal-
loon mitral valvotomy. The American Journal of Cardiology, 1988. 62(4): pp. 264-269.
[17] Nath, R.K. and D.K. Soni, Retrograde non trans-septal balloon mitral valvotomy in mitral 
stenosis with interrupted inferior vena cava, left superior vena cava, and hugely dilated coronary 
sinus. Catheterization and Cardiovascular Interventions, 2015. 86(7): pp. 1289-1293.
[18] Saejueng, B., et al., Transjugular approach as a challenging access in PTMC: case report. 
Journal of the Medical Association of Thailand, 2005. 88(7): pp. 997-1002.
[19] Bahl, V., et al., Balloon mitral valvotomy: comparison between antegrade Inoue and retrograde 
non-transseptal techniques. European Heart Journal, 1997. 18(11): pp. 1765-1770.
[20] Bhat, A., et al., Comparison of percutaneous transmitral commissurotomy with Inoue balloon 
technique and metallic commissurotomy: immediate and short-term follow-up results of a ran-
domized study. American Heart Journal, 2002. 144(6): pp. 1074-1080.
[21] Treviño, A.J., et al., Immediate and long-term results of balloon mitral commissurotomy for 
rheumatic mitral stenosis: comparison between Inoue and double-balloon techniques. American 
Heart Journal, 1996. 131(3): pp. 530-536.
Interventional Cardiology114
[22] Harikrishnan, S., M. Krishnakumar, and K. Suji, 22 inoue and accura balloons—the single 
balloon mitral valvotomy catheters. Percutaneous Mitral Valvotomy. 2012. p. 215.
[23] Hung, J.S. and K.W. Lau, Pitfalls and tips in Inoue balloon mitral commissurotomy. 
Catheterization and Cardiovascular Diagnosis, 1996. 37(2): pp. 188-199.
[24] Sanati, H.R., et al., Percutaneous mitral valvuloplasty using echocardiographic intercommis-
sural diameter as reference for balloon sizing: a randomized controlled trial. Clinical Cardiology, 
2012. 35(12): pp. 749-754.
[25] Sanati, H.R., et al., Percutaneous mitral valvuloplasty—a new method for balloon sizing 
based on maximal commissural diameter to improve procedural results. The American Heart 
Hospital Journal, 2010. 8: pp. 29-32.
[26] Harikrishnan, S., Percutaneous Mitral Valvotomy. 2012: Jaypee Brothers Medical Publishers 
Pvt. Ltd.
[27] Jneid, H., et al., Impact of pre-and postprocedural mitral regurgitation on outcomes after percu-
taneous mitral valvuloplasty for mitral stenosis. The American Journal of Cardiology, 2009. 
104(8): pp. 1122-1127.
[28] Liu, T.-J., et al., Percutaneous balloon commissurotomy reduces incidence of ischemic cere-
bral stroke in patients with symptomatic rheumatic mitral stenosis. International Journal of 
Cardiology, 2008. 123(2): pp. 189-190.
[29] Essop, M.R., et al., Mitral regurgitation following mitral balloon valvotomy. Differing mecha-
nisms for severe versus mild-to-moderate lesions. Circulation, 1991. 84(4): pp. 1669-1679.
[30] Kim, M.-J., et al., Long-term outcomes of significant mitral regurgitation after percutaneous 
mitral valvuloplasty. Circulation, 2006. 114(25): pp. 2815-2822.
[31] Kaul, U., et al., Mitral regurgitation following percutaneous transvenous mitral commissurot-
omy: a single-center experience. The Journal of Heart Valve Disease, 2000. 9(2): pp. 262-266, 
discussion 266-268.
[32] Kang, D.-H., et al., Long-term clinical and echocardiographic outcome of percutaneous mitral 
valvuloplasty: randomized comparison of Inoue and double-balloon techniques. Journal of the 
American College of Cardiology, 2000. 35(1): pp. 169-175.
[33] Krishnamoorthy, K., S. Radhakrishnan, and S. Shrivastava, Natural history and predic-
tors of moderate mitral regurgitation following balloon mitral valvuloplasty using Inoue balloon. 
International Journal of Cardiology, 2003. 87(1): pp. 31-36.
[34] Cheng, T.O., Mechanism of spontaneous diminution of mitral regurgitation following percuta-
neous mitral valvuloplasty with the Inoue balloon. International Journal of Cardiology, 2004. 
93(2): p. 329.
[35] Casale, P., et al., Atrial septal defect after percutaneous mitral balloon valvuloplasty: immediate results 
and follow-up. Journal of the American College of Cardiology, 1990. 15(6): pp. 1300-1304.
Percutaneous Balloon Mitral Valvuloplasty
http://dx.doi.org/10.5772/67757
115
[36] Arora, R., et al., Atrial septal defect after balloon mitral valvuloplasty: a transesophageal echo-
cardiographic study. Angiology, 1993. 44(3): pp. 217-221.
[37] Cequier, A., et al., Left-to-right atrial shunting after percutaneous mitral valvuloplasty. 
Incidence and long-term hemodynamic follow-up. Circulation, 1990. 81(4): pp. 1190-1197.
[38] Fawzy, M.E., et al., Immediate and long-term results of mitral balloon valvotomy for resteno-
sis following previous surgical or balloon mitral commissurotomy. The American Journal of 
Cardiology, 2005. 96(7): pp. 971-975.
[39] McFaul, P., et al., Pregnancy complicated by maternal heart disease. A review of 519 women. 
BJOG: An International Journal of Obstetrics & Gynaecology, 1988. 95(9): pp. 861-867.
[40] Zitnik, R.S., et al., Pregnancy and open-heart surgery. Circulation, 1969. 39(5S1): pp. 
I-257–I-262.
[41] Nercolini, D.C., et al., Percutaneous mitral balloon valvuloplasty in pregnant women with 
mitral stenosis. Catheterization and Cardiovascular Interventions, 2002. 57(3): pp. 318-322.
[42] Esteves, C.A., et al., Immediate and long-term follow-up of percutaneous balloon mitral val-
vuloplasty in pregnant patients with rheumatic mitral stenosis. The American Journal of 
Cardiology, 2006. 98(6): pp. 812-816.
[43] Nobuyoshi, M., et al., Indications, complications, and short-term clinical outcome of percutane-
ous transvenous mitral commissurotomy. Circulation, 1989. 80(4): pp. 782-792.
[44] Iung, B., et al., Immediate results of percutaneous mitral commissurotomy a predictive model on 
a series of 1514 patients. Circulation, 1996. 94(9): pp. 2124-2130.
Interventional Cardiology116
